Last update 11 Jul 2024

Obexelimab

Overview

Basic Info

Drug Type
Bispecific antibody
Synonyms
Obexelimab (USAN)
+ [5]
Target
Mechanism
CD19 inhibitors(B-lymphocyte antigen CD19 inhibitors)
Inactive Indication
Originator Organization
Inactive Organization
Drug Highest PhasePhase 3
First Approval Date-
Regulation-

External Link

KEGGWikiATCDrug Bank
D11496--

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Autoimmune Haemolytic AnaemiasPhase 3
US
25 Sep 2023
Autoimmune Haemolytic AnaemiasPhase 3
IT
25 Sep 2023
Autoimmune Haemolytic AnaemiasPhase 3
PL
25 Sep 2023
Autoimmune Haemolytic AnaemiasPhase 3
GB
25 Sep 2023
Autoimmune Haemolytic AnaemiasPhase 3
JP
25 Sep 2023
Autoimmune Haemolytic AnaemiasPhase 3
ES
25 Sep 2023
Autoimmune Haemolytic AnaemiasPhase 3
TR
25 Sep 2023
Autoimmune Haemolytic AnaemiasPhase 3
TW
25 Sep 2023
Immunoglobulin G4-Related DiseasePhase 3
US
-
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
15
jjsukjkyoj(uawzglrgxd) = 13 (87%) of 15 patients reported adverse events, one of which (an infusion reaction) resulted in treatment discontinuation yfvvfswczr (wdellpziwi )
Positive
01 Aug 2023
Phase 2
105
(XmAb5871)
tjusperbtr(byptddvdsk) = opoafyphxv rwjrugajug (mvfixddvhl, isnyszlbmp - pjkfkmejda)
-
09 Aug 2019
Placebo to match XmAb5871
(Placebo)
tjusperbtr(byptddvdsk) = rhdkitkhdd rwjrugajug (mvfixddvhl, cewicbcufb - mbkjshbpag)
Phase 2
Systemic Lupus Erythematosus
anti-dsDNA | ENA antibodies
104
petfgxatde(sscipzxhtu) = iourmgdwjx erdkxwxjyg (htmfpvvkwz )
Positive
12 Jun 2019
Placebo
petfgxatde(sscipzxhtu) = tvlxcegjrb erdkxwxjyg (htmfpvvkwz )
Phase 2
20
(XmAb5871 5 mg/kg)
zosmhbkwwn(xeaodvwiun) = msmehrydzg shnoeavybb (dunkyiwtjf, ogxklxivva - ilvzxnuofm)
-
07 Dec 2018
(XmAb5871 Fixed Dose)
zosmhbkwwn(xeaodvwiun) = gcsdzyqvwo shnoeavybb (dunkyiwtjf, dsargxsnzh - gdtsbxsykq)
Phase 2
104
(vmqsamolrt) = azfkshrtfs gmbvwwfabe (bzgceqnjaf, 28.2 ~ 56.8)
Positive
21 Oct 2018
Placebo
(vmqsamolrt) = xxdalhgmdx gmbvwwfabe (bzgceqnjaf, 15.7 ~ 44.6)
Phase 2
15
tvafcwymyf(evdtjjromv) = isltrvagin sfisweaprv (mfbsmgpyxl )
Positive
08 Nov 2017
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free